Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
ARCT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.04 - $23.60
Previous CloseN/A
Volume109.32K
Average Volume (3M)765.89K
Market Cap
$514.58M
Enterprise Value$128.45M
Total Cash (Recent Filing)$196.47M
Total Debt (Recent Filing)$22.93M
Price to Earnings (P/E)―
Beta2.52
Next Earnings
Nov 05, 2025EPS Estimate
-0.83Last Dividend Ex-Date
Jan 08, 2013Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding27,154,530
10 Day Avg. Volume1,078,244
30 Day Avg. Volume765,886
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.25
Enterprise Value/Revenue1.09
Enterprise Value/Gross Profit2.43
Enterprise Value/Ebitda-2.32
Forecast
1Y Price Target
$52.40Price Target Upside170.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Financial StabilityARCT ended the quarter with a cash position of $253.4MM, which is sufficient to fund operations into 2028.
Market OpportunityARCT-032 could eventually generate ~$1B+ as it opens the door to ~8% of the CF market, targeting patients ineligible for modulators.
Phase II DataAnalyst is positively inclined towards the interim Phase II data of ARCT-032 in cystic fibrosis due to the lucrative market opportunity and major unmet need.
Bears Say
Price Target AdjustmentThe price target is now adjusted to $42 from a prior $45, reflecting updated model assumptions.
Stock Price RiskWeak data with ≤3% FEV1 absolute change and high variability could potentially cut the stock by 50%.
Arcturus Therapeutics News
ARCT FAQ
What was Arcturus Therapeutics’s price range in the past 12 months?
Arcturus Therapeutics lowest stock price was $8.04 and its highest was $23.59 in the past 12 months.
What is Arcturus Therapeutics’s market cap?
Arcturus Therapeutics’s market cap is $514.58M.
When is Arcturus Therapeutics’s upcoming earnings report date?
Arcturus Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 22 days.
How were Arcturus Therapeutics’s earnings last quarter?
Arcturus Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.892 by $0.552.
Is Arcturus Therapeutics overvalued?
According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued.
Does Arcturus Therapeutics pay dividends?
Arcturus Therapeutics pays a Notavailable dividend of $0.06 which represents an annual dividend yield of N/A. See more information on Arcturus Therapeutics dividends here
What is Arcturus Therapeutics’s EPS estimate?
Arcturus Therapeutics’s EPS estimate is -0.83.
How many shares outstanding does Arcturus Therapeutics have?
Arcturus Therapeutics has 27,154,530 shares outstanding.
What happened to Arcturus Therapeutics’s price movement after its last earnings report?
Arcturus Therapeutics reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.892. Following the earnings report the stock price went up 30.729%.
Which hedge fund is a major shareholder of Arcturus Therapeutics?
Currently, no hedge funds are holding shares in ARCT
Arcturus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.40 (170.24% Upside)
$52.40 (170.24% Upside)
Blogger Sentiment
Bullish
ARCT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 293.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 18.1%
Last 30 Days ▲ 18.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.05%
12-Months-Change
Fundamentals
Return on Equity
-24.57%
Trailing 12-Months
Asset Growth
-20.42%
Trailing 12-Months
Company Description
Arcturus Therapeutics
Arcturus Therapeutics is a clinical-stage biotechnology company focused on the development of innovative RNA medicines. The company operates primarily in the therapeutic sectors of infectious diseases, rare diseases, and other high unmet medical needs. Arcturus is known for its proprietary LUNAR™ delivery technology, which enables the effective delivery of RNA therapeutics, including mRNA vaccines and therapeutics for diseases such as COVID-19, cystic fibrosis, and various liver disorders.
ARCT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with significant progress in key therapeutic programs, financial stability, and advancements in regulatory processes. Despite the decrease in revenue, the company's strategic restructuring and strong financial position, along with promising clinical trial results, contribute to an optimistic future outlook.View all ARCT earnings summariesARCT Stock 12 Month Forecast
Average Price Target
$52.40
▲(170.24% Upside)
Technical Analysis
Rigel
―
Arvinas Holding Company
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Erasca
―
Ownership Overview
8.42% Insiders
30.36% Mutual Funds
31.09% Other Institutional Investors
11.36% Public Companies and Individual Investors